Insider Trading April 3, 2026

Astera Labs GC Executes $1.07M Sale Under Rule 10b5-1; Company Posts Strong Q4 2025 Results

Philip Mazzara sold 9,900 shares in automatic trades as ALAB stock displays wide short- and long-term swings

By Nina Shah ALAB
Astera Labs GC Executes $1.07M Sale Under Rule 10b5-1; Company Posts Strong Q4 2025 Results
ALAB

Philip Mazzara, general counsel and secretary of Astera Labs, sold 9,900 shares on April 1, 2026, under a pre-arranged Rule 10b5-1 plan, realizing $1.07 million in proceeds. The trades were executed at multiple prices and left Mazzara with direct ownership of 118,084 shares. The move comes amid notable ALAB stock volatility and after the company reported robust Q4 2025 results.

Key Points

  • General counsel Philip Mazzara sold 9,900 ALAB shares for $1.07 million under a Rule 10b5-1 plan.
  • Sales executed across five price points; Mazzara holds 118,084 shares after the transactions.
  • ALAB reported Q4 2025 EPS of $0.58 and revenue of $270.6 million, with the stock showing notable volatility.

Philip Mazzara, General Counsel and Secretary of Astera Labs, Inc. (NASDAQ:ALAB), completed a series of automatic sales of company common stock on April 1, 2026, disposing of 9,900 shares for aggregate proceeds of $1.07 million. The disposition was carried out under a pre-established Rule 10b5-1 trading arrangement that Mazzara adopted on May 29, 2025.

The sales were executed at a range of prices. Transaction-level detail shows 3,100 shares sold at an average of $106.3426, 1,985 shares at $107.5416, 3,415 shares at $108.4046, 1,000 shares at $109.156, and 500 shares at $110.346. These weighted average prices together produced the $1.07 million total value reported.

Following the April 1 trades, Mazzara directly holds 118,084 shares of Astera Labs common stock. The trades were automatic under the Rule 10b5-1 framework, meaning they were pre-arranged and executed in accordance with the plan's parameters.

The stock has experienced meaningful swings in recent periods. Over the past six months ALAB has fallen 42%, while over the trailing 12 months it has climbed 110%. At the time of the filing, the share price was quoted at $117.14, which is above the range of prices at which Mazzara sold his shares on April 1.

In valuation commentary included with the disclosure, InvestingPro analysis flagged ALAB as appearing overvalued relative to its Fair Value and noted there are 16 additional ProTips available to subscribers. The platform also advertises a comprehensive Pro Research Report that covers ALAB among more than 1,400 U.S. equities for subscribers seeking further detail.

Separately, Astera Labs reported fourth-quarter 2025 financial results that exceeded consensus earnings expectations. The company posted earnings per share of $0.58, which was 13.73% higher than the $0.51 forecast. Revenue for the quarter reached $270.6 million, representing year-over-year growth of 92%. Those operating results were highlighted alongside the insider transaction but were reported without additional commentary on their effect on the stock price.


Summary

Astera Labs' general counsel sold 9,900 shares under a Rule 10b5-1 plan on April 1, 2026, for $1.07 million. The stock has shown large short- and long-term moves, trading at $117.14 after the sale, and the company reported strong Q4 2025 earnings and revenue growth.

Key points

  • Mazzara sold 9,900 shares on April 1, 2026, totaling $1.07 million under a Rule 10b5-1 plan adopted May 29, 2025.
  • The sales were executed across five price points; Mazzara retains direct ownership of 118,084 shares after the transactions.
  • ALAB stock has been volatile - down 42% over six months but up 110% over one year - and the company reported Q4 2025 EPS of $0.58 and revenue of $270.6 million, a 92% year-over-year increase.

Risks and uncertainties

  • Market volatility: ALAB's substantial six-month decline and one-year gain indicate price volatility that can affect shareholders and market perception.
  • Valuation concerns: InvestingPro analysis indicates the stock appears overvalued relative to its Fair Value, which could influence investor appetite.
  • Insider selling optics: Although the trades were executed under a pre-arranged plan, insider sales can be interpreted in different ways by market participants, potentially impacting sentiment in the technology and capital markets sectors.

Risks

  • ALAB has shown large price swings that introduce market volatility risk affecting equity investors and tech sector sentiment.
  • InvestingPro flagged ALAB as appearing overvalued relative to its Fair Value, posing valuation risk to prospective buyers.
  • Insider sales executed under a Rule 10b5-1 plan may still affect investor perception and trading behavior in the capital markets.

More from Insider Trading

Immunome CFO Disposes $1.4 Million in Stock; Exercises Options Apr 3, 2026 Immunome CSO Executes Planned Sale of $204,238 in Shares Apr 3, 2026 Ciena Senior VP Disposes $9.0 Million in Shares as Company Nears 52-Week High Apr 3, 2026 Kratos CFO Sells 5,000 Shares Under Prearranged Plan; Company Logs Multiple Defense Contracts and Appointments Apr 3, 2026 Photronics Director Disposes of $423K in Shares Amid Positive Quarterly Results Apr 3, 2026